Article
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
Journal of viral hepatitis - 1 Feb 2018
Shafran S D, Shaw D, Charafeddine M, Agarwal K, Foster G R, Abunimeh M, Pilot-Matias T, Pothacamury R K, Fu B, Cohen E, Cohen D E, Gane E
Abstract excerpt
The efficacy and safety of an investigational combination of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) plus sofosbuvir (SOF) ± ribavirin (RBV) in patients with HCV genotype 2 or 3 infection with or without cirrhosis was evaluated. Patients with HCV genotype 3 infection without cirrhosis were randomized to receive OBV/PTV/r + SOF ± RBV for 12 weeks; OBV/PTV/r + SOF + RBV was administered to genotype 3-infected...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.